| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.04 (0%) | 🛒 Add to cart |
| 60 | $1.07 | $82.07 $64.06 (22%) | 🛒 Add to cart |
| 90 | $0.97 | $123.11 $87.08 (29%) | 🛒 Add to cart |
| 120 | $0.93 | $164.15 $111.10 (32%) | 🛒 Add to cart |
| 180 | $0.87 | $246.22 $157.14 (36%) | 🛒 Add to cart |
| 270 | $0.84 | $369.34 $227.21 (38%) | 🛒 Add to cart |
| 360 | $0.83
Best per pill | $492.45 $297.27 (40%) | 🛒 Add to cart |
Similar products
More info:
Bupropion: Effective Depression and Smoking Cessation Treatment - Evidence-Based Review
Bupropion represents one of the more fascinating psychotropic agents in our modern arsenal—an atypical antidepressant that defies easy categorization. Unlike the classic SSRIs that dominated the 1990s, bupropion operates through a completely different mechanism, primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI). We initially viewed it as just another antidepressant option, but over two decades of clinical use have revealed applications far beyond depression—from smoking cessation to off-label uses in ADHD and weight management.
Bupron SR: Effective Depression Management with Reduced Side Effects - Evidence-Based Review
Bupropion SR, or bupron sr as it’s often abbreviated in clinical shorthand, represents one of those interesting second-generation antidepressants that really changed our approach to depression treatment. Unlike the older tricyclics that came with significant anticholinergic side effects, this norepinephrine-dopamine reuptake inhibitor (NDRI) offered a different mechanism that proved particularly valuable for patients who couldn’t tolerate SSRIs. The sustained-release formulation was the real game-changer though - it smoothed out those peak-trough fluctuations that made the immediate-release version challenging for some patients.
champix
Let me tell you about Champix - or varenicline, as we know it in clinical practice. This smoking cessation aid has been one of the most fascinating and challenging medications I’ve worked with over my 25 years in addiction medicine. When Pfizer first introduced this selective nicotinic receptor partial agonist back in 2006, our entire department was skeptical but cautiously optimistic. We’d been through nicotine replacement therapies, bupropion, and countless behavioral interventions with mixed results.
contrave
Contrave represents one of the more interesting pharmacological approaches to weight management we’ve seen in recent years. It’s not a single molecule but rather a fixed-dose combination product containing naltrexone HCl and bupropion HCl in an extended-release formulation. What’s fascinating clinically is how it leverages two established CNS-active drugs with completely different primary indications to create a novel therapeutic effect for chronic weight management. I remember when the trial data first started coming in – our endocrinology department had some heated debates about whether this dual-mechanism approach would prove more effective than single-agent therapies.
cymbalta
Duloxetine hydrochloride, marketed under the brand name Cymbalta, represents a significant advancement in psychopharmacology as a serotonin-norepinephrine reuptake inhibitor (SNRI). Unlike earlier antidepressants that primarily targeted serotonin alone, this dual mechanism provides broader neuromodulatory effects that have proven particularly valuable for conditions where both pain pathways and mood regulation are disrupted. We initially viewed it as just another SSRI alternative back in 2004 when it first got FDA approval, but the clinical reality turned out to be much more nuanced.
desyrel
TraZODone hydrochloride, commonly known by its brand name Desyrel, is an antidepressant medication belonging to the class of serotonin antagonist and reuptake inhibitors (SARIs). Initially developed in the 1970s and approved by the FDA in 1982, it occupies a unique niche in psychopharmacology due to its multifaceted mechanism. While primarily indicated for major depressive disorder, its strong sedative properties have made it a versatile agent in managing insomnia, particularly in patients where traditional sleep aids are contraindicated.
emsam
Let me tell you about EMSAM - this transdermal MAOI patch that’s been one of the most fascinating tools in my depression treatment arsenal over the past fifteen years. When I first encountered it back in 2007, I’ll admit I was skeptical. Another antidepressant? But the delivery system - a patch that delivers selegiline through the skin - that got my attention. The thing about EMSAM is it bypasses the first-pass metabolism entirely.
female cialis
Product Description: Let me walk you through what we’re actually dealing with here. When patients started asking about “female Cialis” about eight years ago, my initial reaction was skepticism - we don’t have a direct female equivalent to tadalafil, but what we do have is a complex interplay of physiological mechanisms that can address female sexual dysfunction. The landscape has evolved significantly since those early days when we’d just throw hormone replacements at everything and hope for the best.
flibanserin
Flibanserin is a centrally-acting, multifunctional serotonin receptor agonist and antagonist that was originally investigated as an antidepressant before being repurposed for a very specific indication in women’s health. What’s fascinating about this compound is how it challenges our traditional understanding of pharmacodynamics – it’s not simply an SSRI, nor is it a hormone, but rather a novel approach to modulating neurotransmitter systems involved in desire and arousal. I remember when we first started working with this medication back in 2012, our entire department was divided.